Here are five points:
1. The company plans to use the funding to boost the commercialization of its cervical fusion technology portfolio.
2. London, U.K.-based MVM Life Science Partners, a new investor, led the financing. The company is now a part of Providence's board of directors.
3. Jupiter, Fla.-based Stanmore Medical Investments and Mill Valley, Calif.-based Aphelion Capital also participated in the financing round.
4. Providence develops tissue-sparing, cervical fusion technology.
5. The company is currently working on commercializing the DTRAX platform of single-use, tissue-sparing instruments and CAVUX implants for cervical fusion.
More articles on devices:
Zimmer Biomet's growth strategy in spine: MIS, cervical and becoming a 'health solutions provider'
Predictive Technology Group highlights US patent allowance for treating patients with genetic spinal deformities, syndromes: 5 highlights
Global wearable medical devices market to hit $12.1B by 2021: 9 observations